



Recently Introduced Products

Drug Name	Indication	Potential Impact	Expected Avg. Annual Cost
Invega 3mg, 6mg, and 9mg Tablets	For the treatment of schizophrenia.	\$	\$1233.70 - \$3693.80
Isentress Tablet	For the treatment of HIV-1 infection, in combination with other antiretroviral agents.	\$	\$9855
Tridural 100mg, 200mg, and 300mg Tablets	For moderate pain management in adults who require treatment for several days or more.	\$	\$401.50 - \$1113.25

\$: Est. drug plan expenditure increase of <1%* \$\$: Est. drug plan expenditure increase of 1-5%* \$\$\$: Est. drug plan expenditure increase of >5%*

Celsentri™ - A Novel Antiretroviral Agent

Celsentri™ is an antiretroviral agent for treatment-experienced adult patients infected with CCR5-tropic HIV-1. It is given in combination with other antiretroviral agents in patients during the advanced stages of HIV who have evidence of resistance to multiple antiretroviral drug.¹

AIDS has claimed 2.9 Million lives in 2006 despite improved access to patient care and antiretroviral drugs, in many countries all over the world. An estimated 39.5 Million people are living with HIV-1 representing the highest level ever - In 2006, 4.3 million people were newly infected.²

Celsentri cost approximately \$12,045 per year (not including the cost of other antiretroviral drugs to be given at the same time). The direct cost is difficult to ascertain because the distribution of care and the treatment costs shift according to the disease stage. The last two stages of HIV/AIDS accounts for 59% of the total health care costs. Collectively, indirect costs are estimated to be 2.4 times more than the direct costs of treating HIV/AIDS, in Canada.² Newer antiretroviral agents, such as Celsentri™, control viral replication and delay the onset of AIDS and ultimately improve the quality of life for HIV patients.

Many ClaimSecure clients will fully cover Celsentri™ under their existing open drug formularies as determined by contractual agreements. For clients who subscribe to ClaimSecure Managed Formularies, the drug will be placed under Special Authorization. Under the Special Authorization program, the priority will be to co-ordinate coverage with the provincial drug programs. In addition, applicants will only be approved for the special authorization exception status after meeting the pre-determined clinical criteria.

If you require additional information about Celsentri™, please contact Shellina Sevany, Manager, Clinical Services Department, at (905) 949-3025 or 1-888-479-7587 ext.3025.

Recommendation: Special Authorization

ClaimSecure reserves the right to amend in part or in its entirety stated special authorization clinical guidelines

References:

- 1) Celsentri™ Product Monograph. Pfizer Canada Inc., September 19, 2007.
- 2) Celsentri™ Private Payer Submission Binder. Pfizer Canada Inc., November, 2007.

HEALTH LIBRARY | MENU SANTÉ



claimsecure.com / securindemnite.com

* Based on the Financial Impact Analysis per 100 000 lives covered
© 2007 ClaimSecure Inc.